Drug-Drug Interaction Study Between CJ-12420 and Clarithromycin in Healthy Male Subjects

HK inno.N logo

HK inno.N

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: CJ-12420 200mg
Drug: CJ-12420 200mg + Clarithromycin 500mg
Drug: Clarithromycin 500mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT02052336
CJ_APA_103

Details and patient eligibility

About

Primary Objective: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin. Secondary Objective(s): To assess the safety of the coadministration of multiple dose of CJ-12420 and clarithromycin in healthy subjects

Full description

An open-label, randomized, 6-sequence, 3-period, 3-treatment crossover design

Enrollment

24 patients

Sex

Male

Ages

19 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male volunteers in the age between 19 and 45 years old
  • Body mass index(BMI) in the range of 19 to 28 kg/m2
  • Understand the requirement of the study and voluntarily consent to paticipate in the study

Exclusion criteria

  • History of clinically significant medical history or disease (hepatic, kidney, gastrointestinal,respiratory, musculoskeletal, endocrine,neuro-psychiatric, haemato-oncologic,urinary tract, cardiac arrhythmia and cardiovascular system) judged by investigator.
  • Clinically significant abnormal laboratory results within at least 28 days prior to the first day of drug administration. AST or ALT > 1.25 times of upper limit value Total bilirubin > 1.5 times of upper limit value estimated GFR :less than 80 mL/min
  • Clinically significant abnormal ECG results within at least 28 days prior to the first day of drug administration PR ≥ 210 msec QRS ≥ 120 msec QT ≥ 500 msec QTcF ≥ 500 msec
  • Clinically significant hypersensitivity reaction against investigational drug or other drugs
  • history of drug abuse or "positive" results from drug screening test.
  • Take medicine such as prescription medicine or herbal medicine, over-the-counter drug, vitamin supplements
  • Person who have intake history of food or drug which can affect drug absorption, drug distribution, drug metabolism, and drug excretion and bowel activity
  • Volunteer have a history of donation of whole blood donation, apheresis, transfusion
  • Volunteer a heavy drinker(30g/day), smoker(10 cigarettes/day), heavy caffeine consumer(400mg/day)

Trial design

24 participants in 3 patient groups

CJ-12420 200 mg + Clarithromycin 500mg
Experimental group
Description:
CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days
Treatment:
Drug: Clarithromycin 500mg
Drug: CJ-12420 200mg
CJ-12420 200mg
Active Comparator group
Description:
CJ-12420 200mg QD for 5 days
Treatment:
Drug: Clarithromycin 500mg
Drug: CJ-12420 200mg + Clarithromycin 500mg
Clarithromycin 500mg
Active Comparator group
Description:
Clarithromycin 500mg BID for 5 days
Treatment:
Drug: CJ-12420 200mg + Clarithromycin 500mg
Drug: CJ-12420 200mg

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems